Colistin in the 21st century
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Colistin is a 50-year-old antibiotic that is being used increasingly as a 'last-line' therapy to treat infections caused by multidrug-resistant Gram-negative bacteria, when essentially no other options are available. Despite its age, or because of its age, there has been a dearth of knowledge on its pharmacological and microbiological properties. This review focuses on recent studies aimed at optimizing the clinical use of this old antibiotic. RECENT FINDINGS: A number of factors, including the diversity in the pharmaceutical products available, have hindered the optimal use of colistin. Recent advances in understanding of the pharmacokinetics and pharmacodynamics of colistin, and the emerging knowledge on the relationship between the pharmacokinetics and pharmacodynamics, provide a solid base for optimization of dosage regimens. The potential for nephrotoxicity has been a lingering concern, but recent studies provide useful new information on the incidence, severity and reversibility of this adverse effect. Recent approaches to the use of other antibiotics in combination with colistin hold promise for increased antibacterial efficacy with less potential for emergence of resistance. SUMMARY: Because few, if any, new antibiotics with activity against multidrug-resistant Gram-negative bacteria will be available within the next several years, it is essential that colistin is used in ways that maximize its antibacterial efficacy and minimize toxicity and development of resistance. Recent developments have improved use of colistin in the 21st century.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Self-citationTalbot, G. H., Bradley, J., Edwards, J. E., Gilbert, D., Scheld, M., & Bartlett, J. G. (2006) · Clinical Infectious Diseases · doi:10.1086/499819 · Cited by 1,104
Hancock, R. E. (1997) · The Lancet · doi:10.1016/s0140-6736(97)80051-7 · Cited by 1,096
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies
Falagas, M. E., & Kasiakou, S. K. (2006) · Critical Care · doi:10.1186/cc3995 · Cited by 828
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria
Li, J., Nation, R. L., Milne, R. W., Turnidge, J. D., & Coulthard, K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.10.001 · Cited by 571
Self-citationLandman, D., Georgescu, C., Martin, D. A., & Quale, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00006-08 · Cited by 565
Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii
Li, J., Rayner, C. R., Nation, R. L., Owen, R. J., Spelman, D., Tan, K. E., & Liolios, L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00103-06 · Cited by 548
Self-citation
Cited by
Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria
Olaitan, A. O., Morand, S., & Rolain, J.-M. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00643 · Cited by 1,395
Colistin: an update on the antibiotic of the 21st century
Biswas, S., Brunel, J.-M., Dubus, J.-C., Reynaud-Gaubert, M., & Rolain, J.-M. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.78 · Cited by 581
Pharmacology of Polymyxins: New Insights into an ‘Old‘ Class of Antibiotics
Velkov, T., Roberts, K. D., Nation, R. L., Thompson, P. E., & Li, J. (2013) · Future Microbiology · doi:10.2217/fmb.13.39 · Cited by 452
Self-citationTowards Understanding MCR-like Colistin Resistance
Sun, J., Zhang, H., Liu, Y.-H., & Feng, Y. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.02.006 · Cited by 446
Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing
Lim, L. M., Ly, N., Anderson, D., Yang, J. C., Macander, L., Jarkowski, A., Forrest, A., Bulitta, J. B., & Tsuji, B. T. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.12.1279 · Cited by 444
Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications
Iredell, J., Brown, J., & Tagg, K. (2016) · BMJ · doi:10.1136/bmj.h6420 · Cited by 392
Plasmids, a molecular cornerstone of antimicrobial resistance in the One Health era
Castañeda-Barba, S., Top, E. M., & Stalder, T. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00926-x · Cited by 379
Nation, R. L., Li, J., Cars, O., Couet, W., Dudley, M. N., Kaye, K. S., Mouton, J. W., Paterson, D. L., Tam, V. H., Theuretzbacher, U., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70850-3 · Cited by 354
Self-citationStokes, J. M., MacNair, C. R., Ilyas, B., French, S., Côté, J.-P., Bouwman, C., Farha, M. A., Sieron, A. O., Whitfield, C., Coombes, B. K., et al. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.28 · Cited by 340
Dhingra, S., Rahman, N. A. A., Peile, E., Rahman, M., Sartelli, M., Hassali, M. A., Islam, T., Islam, S., & Haque, M. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.535668 · Cited by 329
Molecular mechanisms related to colistin resistance in Enterobacteriaceae
Aghapour, Z., Gholizadeh, P., Ganbarov, K., bialvaei, A. Z., Mahmood, S. S., Tanomand, A., Yousefi, M., Asgharzadeh, M., Yousefi, B., & Samadi Kafil, H. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s199844 · Cited by 320
Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?
Nation, R. L., Velkov, T., & Li, J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu213 · Cited by 310
Self-citationMobilized colistin resistance (mcr) genes from 1 to 10: a comprehensive review
Hussein, N. H., AL-Kadmy, I. M. S., Taha, B. M., & Hussein, J. D. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06307-y · Cited by 290
A review on colistin nephrotoxicity
Ordooei Javan, A., Shokouhi, S., & Sahraei, Z. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1865-4 · Cited by 287
The Concept of an Ideal Antibiotic: Implications for Drug Design
Gajdács, M. (2019) · Molecules · doi:10.3390/molecules24050892 · Cited by 271
Colistin: new lessons on an old antibiotic
Yahav, D., Farbman, L., Leibovici, L., & Paul, M. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03734.x · Cited by 259
Strategies for bypassing the membrane barrier in multidrug resistant Gram‐negative bacteria
Bolla, J.-M., Alibert-Franco, S., Handzlik, J., Chevalier, J., Mahamoud, A., Boyer, G., Kieć-Kononowicz, K., & Pagès, J.-M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.04.054 · Cited by 250
“Now, faced with the continuous increase of infectious diseases involving MDR bacteria and with the scarcity of new active antibiotics, polymyxin group represents a last resort for clinicians [33,36,37].”
BackgroundAntibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae
Band, V. I., Crispell, E. K., Napier, B. A., Herrera, C. M., Tharp, G. K., Vavikolanu, K., Pohl, J., Read, T. D., Bosinger, S. E., Trent, M. S., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.53 · Cited by 248
“Multi-drug resistant Enterobacter spp. have increasingly emerged as a cause of hospital-acquired infections 3–5 , with the drug colistin being relied on as a last line of treatment 6,7 .”
Catry, B., Cavaleri, M., Baptiste, K., Grave, K., Grein, K., Holm, A., Jukes, H., Liebana, E., Navas, A. L., Mackay, D., et al. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.06.005 · Cited by 238
Drug release from nanomedicines: selection of appropriate encapsulation and release methodology
Wallace, S. J., Li, J., Nation, R. L., & Boyd, B. J. (2012) · Drug Delivery and Translational Research · doi:10.1007/s13346-012-0064-4 · Cited by 217
Self-citationTreatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections
Neuner, E. A., Yeh, J.-Y., Hall, G. S., Sekeres, J., Endimiani, A., Bonomo, R. A., Shrestha, N. K., Fraser, T. G., & van Duin, D. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.10.013 · Cited by 166
“Neurotoxicity is another concerning side effect (Nation and Li, 2009).”
Manohar, P., Shanthini, T., Ayyanar, R., Bozdogan, B., Wilson, A., Tamhankar, A. J., Nachimuthu, R., & Lopes, B. S. (2017) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000508 · Cited by 104
“The paucity of new antibiotics for a decade has allowed clinicians to reconsider colistin as an alternative therapeutic option against infections caused by Gram-negative bacteria [11].”
Background
Metadata
- Authors
- Nation, R. L., & Li, J.
- Venue
- Current Opinion in Infectious Diseases
- Published
- 2009-12
- Volume
- 22
- Issue
- 6
- Pages
- 535-543
- ISSN
- 0951-7375 (ISSN-L)
- OpenAlex
- W1967459325
- Cited by
- 443
- References
- 59
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.